A trial of directed therapy in younger patients with acute myeloid leukaemia: MRC AML 15

Conditions

Leukaemia Cancer Leukaemia

Dima El‐Sharkawi, Duncan Sproul, Christopher Allen, Andrew Feber, Melissa Wright et al. (8 authors)

Haematologica2017-10-1213 citations

10.3324/haematol.2017.173096

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Steven Knapper, Nigel H. Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale et al. (13 authors)

Blood2016-11-21143 citations

10.1182/blood-2016-07-730648

Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia

David C. Linch, Robert K. Hills, Alan K. Burnett, Asim Khwaja, Rosemary E. Gale

Blood2014-05-23119 citations

10.1182/blood-2014-02-554667

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK, National Cancer Research Institute Adult Leukaemia Working Group.

2010-04-121,481 citations

10.1182/blood-2009-11-254441

Interventions

1. (R1) Patients with acute promyelocytic leukemia (APL) will be randomised to receive oral retinoic acid together with either MRC H-DAT chemotherapy or the Spanish Intermittent Idarubicin. Following

Eligibility

Inclusion criteria

Inclusion criteria: 1. Any form of de novo or secondary AML 2. Suitable for intensive chemotherapy 3. Under 60 years 4. Written consent

Exclusion criteria

Exclusion criteria: 1. Previous chemotherapy for AML 2. Blast transferration of CML 3. Pregnant or lactating 4. Abnormal liver function tests for Mylotarg randomisations

Design outcomes

Primary

Measure	Time frame
The main endpoints for each comparison will be: 1. Complete remission (CR) achievement and reasons for failure (for induction questions) 2. Duration of remission, relapse rates and deaths in first CR 3. Overall survival 4. Toxicity, both haematological and non-haematological, and quality of life 5. Supportive care requirements (and other aspects of health economics)	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom, Wales

Outcome results

None listed